Quidel enlisted ICS' multidisciplinary team to be the application developer of the next-generation, fully integrated molecular diagnostic system for its Savanna platform.
The low-cost, point-of-care testing platform allows for easy rapid results for disease states and conditions such as COVID-19, MRSA and HIV.
The Savanna project started with UX design leading to an intuitive CLIA-waived touchscreen interface and an extensible processing architecture. It also includes software applications and powerful, forward-looking cybersecurity for its fleet in the field.
With Savanna, Quidel will deploy a future-proof in-vitro diagnostics platform that's flexible, scalable, configurable and secure.
In its collaboration with ICS, Quidel convenes best-practices from usability, cybersecurity, cloud and user management on an embedded touch-screen platform.
ICS has collaborated with Quidel on other point-of-care technologies, which have received Emergency Use Authorization from the US Food and Drug Administration.
ICS assisted Quidel in bringing development in-house, setting up a new continuous integration system to build the software and run automated unit tests, enabling the generation of new software releases following a development and test process that meets the stringent requirements of medical devices.
ICS also designed and implemented new product features, including an IoT-based facility for software updates and remote device management.
At the intersection of custom software development, engineering and UX design, Integrated Computer Solutions (ICS) has been helping Fortune 1000 companies create transformative products for over 30 years.
ICS is headquartered in Waltham, Mass., with offices in Sunnyvale, California and Ottawa, Ontario.
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
BD receives FDA clearance for Surgiphor 1000mL irrigation system
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
FDA accepts rusfertide NDA and grants priority review for polycythemia vera